Description
Product overview
Retatrutide is a synthetic peptide engineered to activate three distinct receptors simultaneously: GLP-1, GIP, and glucagon. Developed by Eli Lilly. Supplied as 20mg lyophilised per vial. The first triple-agonist in clinical research, with the largest published weight-loss endpoint in the incretin class.
Receptor profile
- GLP-1 receptor — appetite suppression and gastric slowing
- GIP receptor — insulin sensitisation
- Glucagon receptor — energy expenditure, hepatic lipid oxidation
The glucagon arm distinguishes retatrutide from the dual-agonist class. Where tirzepatide and semaglutide act primarily on energy intake, retatrutide also lifts energy expenditure through glucagon receptor activation.
Trial data summary
Phase 2 trial (Jastreboff et al., NEJM 2023): mean body weight reduction of 24.2% at 48 weeks with 12mg weekly dosing — the largest endpoint published for any anti-obesity peptide. The weight loss curve had not plateaued at trial endpoint, suggesting continued benefit with extended exposure. Phase 3 trials are underway.
See our retatrutide research overview and three-way comparison.
Research applications
- Triple-incretin receptor pharmacology
- Glucagon receptor biology research
- Energy expenditure modulation studies
- Hepatic lipid metabolism research
- Advanced metabolic research models
Reconstitution and storage
Reconstitute with bacteriostatic water at 2 mL for ~10 mg/mL working concentration. The triple-agonist architecture is structurally complex — batch-specific CoA verification is non-negotiable for reliable stability data. Refrigerate (2–8°C), stable approximately 4 weeks after reconstitution. Store lyophilised vial at –20°C.
Quality and analytics
HPLC purity ≥98%. Batch-specific Certificate of Analysis with mass spectrometry confirmation available on request.
For laboratory research use only. Not for human or veterinary use.
